NEOADJUVANT IMATINIB AND RADIOTHERAPY IN GASTROINTESTINAL STROMAL TUMOR OF THE RECTUM: A CASE REPORT
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Rectal localization iS rare. The gold standard for treatment is: surgery and tyrosine kinase inhibitors (TKIs) for metastatic or unresectable disease.
We report a case of a 62 year-old woman who underwent a gastroenterology visit for abdominal pain, tenesmus and constipation. After GIST diagnosis and staging, the patient started induction therapy with imatinib followed by concomitant radio and targeted therapy before a sphincter-saving anterior resection, with a regular postoperative course.
The rationale of neoadjuvant treatment is lesion downsizing for an easier surgery. In epithelial cancers treated through concomitant therapies, the goal is also to preserve the functional integrity of organs, lowering the risk for salvage therapies. Also in GISTs, there is a direct correlation between downsizing, downstaging and outcomes. There are few reports about concurrent radio-therapy and TKIs, and this approach iS probably underutilized. Further studies are needed.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.